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The Proto-Oncogene c-maf Is Responsible
for Tissue-Specific Expression of Interleukin-4
I-Cheng Ho, Martin R. Hodge, John W. Rooney,* means to alter Th differentiation is to increase or block
the transcription of selected cytokines. Indeed, adminis-and Laurie H. Glimcher
tration of recombinant IL-4 or antibodies to IL-12 (RackeDepartment of Cancer Biology
et al., 1994; Leonard et al., 1995) ameliorate experimen-Harvard School of Public Health
tal allergic encephalomyelitis, a Th1-driven autoimmuneDepartment of Medicine
disease, while anti-IL-4 antibodies cure the Th2-medi-Harvard Medical School
ated parasitic disease Leishmaniasis major (Sadick etBoston, Massachusetts 02115
al., 1990).
The molecular basis for the tissue-specific expression
of IL-4, or any T cell cytokine, has remained elusive.Summary
One possibility is the presence of repressor proteins that
selectively silence cytokines. Transcriptional silencingThe molecular basis for the distinctive cytokine ex-
has been well documented for bacterial, yeast, andpression of CD41 T helper 1 (Th1) and T helper 2 (Th2)
mammalian genes. Examples include Escherichia colisubsets remains elusive. Here, we report that the
thermoregulation genes (Goransson et al., 1990), yeastproto-oncogene c-maf, a basic region/leucine zipper
a2 mating type genes (Keleher et al., 1988), and mamma-
transcription factor, controls tissue-specific expres-
lian major histocompatibility complex (MHC) class I and
sion of IL-4. c-Maf is expressed in Th2 but not Th1 T cell receptor (TCR)a genes (Weissman and Singer,
clones and is induced during normal precursor cell 1991; Winoto and Baltimore, 1989). Indeed, early experi-
differentiation along a Th2 but not Th1 lineage. c-Maf ments involving injection of IL-2 genomic DNA into Xen-
binds to ac-Maf response element (MARE) in the prox- opus oocytes suggested the existence of a repressor
imal IL-4 promoter adjacent to a site footprinted by protein for IL-2 in resting versus activated T cell extracts
extracts from Th2 but not Th1 clones. Ectopic expres- (Mouzaki et al., 1991). These studies suggested that the
sion of c-Maf transactivates the IL-4 promoter in Th1 absence of IL-2 production in resting T cells was due
cells, B cells, and nonlymphoid cells, a function that to proteins that silenced the transcription of IL-2 by
maps to the MARE and Th2-specific footprint. Further- interacting with negative elements in the IL-2 promoter.
more, c-Maf acts in synergy with the nuclear factor of A second possibility is the existence of Th-selective
activated T cells (NF-ATp) to initiate endogeneous IL-4 transactivators. A family of four related transcription fac-
production by B cells. Manipulation of c-Maf may alter tors called nuclear factor of activated T cells (NF-AT)
Th subset ratios in human disease. plays a key role in the regulation of cytokine gene ex-
pression (Emmel et al., 1989; Flanagan et al., 1991; Jain
et al., 1993; McCaffrey et al., 1993; Rao, 1994; NorthropIntroduction
et al., 1994). However, NF-AT family members bind to
and transactivate the promoters of multiple cytokineCD41T helper (Th) cells are not a homogeneous popula-
genes, including IL-2 and IL-4 (Rooney et al., 1995b;tion but can be divided on thebasis of cytokine secretion
Szabo et al., 1993; Flanagan et al., 1991; Northrop etinto at least two subsets, termed T helper 1 (Th1) and
al., 1994). Thus, they are not likely to direct Th-specificT helper 2 (Th2) (Mosmann et al., 1986; Paul and Seder,
cytokine transcription. Most, if not all, NF-AT binding1994; Seder and Paul, 1994). Th1 cells secrete interleu-
sites incytokine promoter regulatory regions areaccom-kin-2 (IL-2) and interferon-g (IFNg), while Th2 cells pro-
panied by nearby sites that bind auxiliary transcriptionduce IL-4, IL-5, IL-10, and IL-13. Both subsets produce
factors, usually members of the AP-1 family. We andcytokines such as tumor necrosis factor and granulo-
others have shown that NF-AT and AP-1 proteins bindcyte/macrophage colony-stimulating factor. There is
coordinately and cooperatively and are required for fullnow abundant evidence that the ratio of Th1 to Th2 cells
activity of the IL-2 and IL-4 promoters. Different AP-1is highly relevant to the outcome of a wide array of
proteins (c-Jun, c-Fos, Fra-1, Fra-2, JunB, and JunD)immunologically mediated clinical syndromes including
bind to these sites (Rao, 1994; Jain et al., 1993; Boiseautoimmune, allergic, and infectious diseases. There-
et al., 1993; Rooney et al., 1995a, 1995b). However, nofore, the ability to alter ratios of Th1 and Th2 subsets
evidence for the differential recruitment of these AP-1
provides exciting therapeutic options. Such manipula-
family members to the IL-2 or IL-4 promoters has been
tion requires an understanding of the mechanisms by
obtained (Rooney et al., 1995a) and, thus, it is unlikely
which CD4 T helper precursor cells (Thp), which secrete that Th1/Th2 specificity is achieved through selective
only IL-2, differentiate into Th1 or Th2 effector cells. It usage of these proteins.
is clear that the cytokines themselves are potent Th Recently, a new subfamily of AP-1/CREB/ATF pro-
cell inducers and form an autoregulatory loop (Paul and teins has been described. The v-maf oncogene was
Seder, 1994; Seder and Paul, 1994). Thus, IL-4 promotes originally isolated from a spontaneous musculoaponeu-
the differentiation of Th2 cells while preventing the dif- rotic fibrosarcoma of chicken and identified as the trans-
ferentiation of precursors into Th1 cells, while IL-12 and forming gene of the avian retrovirus AS42 (Nishizawa et
IFNg have the opposite effect. Therefore, one possible al., 1989). v-maf encodes a 42 kd basic region/leucine
zipper (b-zip) protein with homology to the c-fos and
c-jun oncogenes. Its cellular homolog, the c-maf proto-*Present address: Department of Molecular and Cell Biology, Uni-
versity of California at Berkeley, Berkeley, CA 94720. oncogene, has only two structural changes in the coding
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region from v-maf and when overexpressed can cause
cellular transformation (Kataoka et al., 1993). The Maf
oncogene family includes the “big” Mafs, which include
c-Maf (isolated from chicken, mouse, and human), MafB
(chicken) and a human retina-specific gene Nrl (Swaroop
et al., 1992) as well as the “small” Mafs, which include
MafK, MafF, MafG and p18, which lack the amino-termi-
nal two-thirds of c-Maf that contains the transactivating
domain (Fujiwara et al., 1993; Igarashi et al., 1995b;
Andrews et al., 1993; Kataoka et al., 1995). c-Maf and
Maf family members form homodimers and heterodim-
ers with each other and with Fos and Jun, consistent
with the known ability of the AP-1 proteins to pair with
each other (Kerppola and Curran, 1994; Kataoka et al.,
1994).The DNAtarget sequence towhich c-Maf homodi-
mers bind, termed the c-Maf response element (MARE),
is a 13 bp or 14 bp element that contains a core T-MARE
(TRE) or C-MARE (CRE) palindrome, respectively. Little
is known about the function of Maf family members,
although c-Maf has been shown to stimulate transcrip-
tion from the Purkinje neuron-specific promoter L7
(Kurschner and Morgan, 1995) and Nrl can drive expres-
sion of the QR1 retina-specific gene (Swaroop et al.,
1992). The small Mafs have been shown to function as
repressors of a- and b-globin transcription when bound
as homodimers but are essential as heterodimeric part-
ners with the erythroid-specific factor p45NF-E2 to acti-
vate globin gene transcription (Kataoka et al., 1995;
Igarashi et al., 1994). MafK overexpression induces
erythroleukemia cell differentiation (Igarashi et al.,
1995a), while MafB interacts with and represses Ets-1
to inhibit erythroid differentiation (Sieweke et al., 1996).
However, there have been no reports implicating c-Maf
or Maf family members in the regulation of genes ex-
pressed in lymphoid cells or in cytokine gene expression
in any tissue.
Here, we present evidence that the c-maf proto-onco-
gene is responsible for the tissue-specific expression
of IL-4 in Th2 cells. Furthermore, it is selectively ex-
pressed in differentiating and mature Th2 cells and is
absent from Th1 cells. To our knowledge, c-maf is the
Figure 1. Cytokine Expression Is Not Due to a Repressoronly gene identified to date, other than the cytokines
(A) Schema of approach as detailed in Experimental Procedures.themselves, to be differentially expressed inTh subsets.
(B) RT–PCR analysis of IL-2 and IL-4 cytokines and control b-actin
mRNA produced by the unfused Th1 clone (D1.1), unfused Th2 clone
(D10), Th1 and Th2 homokaryons, and Th1–Th2 heterokaryons.
Methods are detailed in Experimental Procedures.
Results
Cytokine Specificity Is Due to a Positive homokaryons and served as controls. The three popula-
tions were then stimulated in culture with antibodies toTransacting Factor and Not
to a Repressor CD3 to activate cytokine gene expression, and RNA was
prepared for reverse transcriptase–polymerase chainTissue specificity can be achieved through the action
of repressor or silencer proteins. Thus, it was possible reaction (RT–PCR) and Northern blot analysis. As shown
in Figure 1B, the Th1 and Th2 clones and Th homokary-that the IL-2 and IL-4 genes were actively repressed in
Th2 and Th1 cells respectively. To test for the existence ons transcribed only IL-2 (Th1) or IL-4 (Th2), respectively,
while the Th1/Th2 heterokaryons produced both cyto-of repressor proteins, we performed somatic cell fusions
between a Th1 (D1.1) and a Th2 (D10) clone and took kines. The existence of repressor protein(s) should have
resulted in the extinction of both cytokines in the hetero-advantage of polymorphic cell surface MHC class I anti-
gens to sort the fused cells by flow cytometry into three karyons. Thus, our conclusion from these experiments
was that cytokine specificity was likely mediated bypopulations,as schematized inFigure 1A. Cells express-
ing bothMHC class IKb and Kk markers were heterokary- Th-specific positive transacting factors rather than by
selective silencer proteins.ons, while cells expressing only Kb or Kk represented
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Isolation of a Th2-Specific Gene from a cDNA
Library Prepared from an Anti-CD3-Activated
Th2 Clone
In the course of screening a cDNA library prepared from
an anti-CD3-activated Th2 clone, D10, for NF-AT-inter-
acting proteins by the yeast two-hybrid system, we iso-
lated multiple cDNAs, all of which were extremely weak
interactors. All cDNAs obtained in this screen were next
evaluated for Th-specific expression by Northern blot
analysis using a panel of Th1 and Th2 clones. One such
cDNA, which was repeatedly isolated, detected tran-
scripts present in Th2 clones (D10, CDC35) but not in
either Th1 clones (AR5, OF6, D1) or in a B cell lymphoma,
M12 (Figure 2A). Furthermore, the levels of transcripts
detected in D10 Th2 cells were substantially increased
upon activation by ligation of the TCR with anti-CD3
antibody. No induction of the transcript occurred in
Th1 clones upon anti-CD3 treatment. A control probe,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
demonstrated approximately equal loading of RNA in
all lanes (Figure 2A). Thus, the expression of this cDNA
in the lymphoid lineage appeared to be Th2-specific and
sensitive to signals transmitted through the TCR.
To determine whether the expression of this gene was
tissue specificand regulatedduring thecourse of normal
Th cell development, Thp spleen cells were differenti-
ated in vitro (Hsieh et al., 1995). Naive spleen Thp cells
were driven along a Th1 or Th2 pathway by treatment
with anti-CD3 in the presence of cytokines and anticy-
tokine antibodies (IFNg and anti-IL-4 for Th1, IL-4 and
anti-IFNg for Th2). Northern blot analysis of differentiat-
ing cells harvested at various time-points after stimula-
tion in a primary (day 0–8) and secondary (0–20 hr)
response was performed (Figure 2B, bottom) and identi-
fication of differentiating Thp cells as Th1 or Th2 was
determined by analyzing culture supernatants by en-
zyme-linked immunosorbent assay (ELISA) for IL-10
(Figure2B, top) and IFNg (data not shown). In two experi-
ments, this analysis revealed low level (Figure 2B) or
undetectable (data not shown) expression of this cDNA
in naive spleen cells at day 0, while in cultures differenti-
ating along a Th2 pathway, substantial induction of tran-
scripts occurred by day 8 in a primary stimulation and
by hour 20 in a secondary stimulation. In contrast, no
induction occurred in cells being driven along a Th1
pathway. A control probe (GAPDH) showed approxi-
matelyequal loading of RNA in all lanes (data not shown).
The low level of transcripts present in cells being driven
Figure 2. Northern Blot Analysis of the cDNA Clone Isolated fromalong a Th1 pathway likely reflects the presence of resid-
an Activated D10 Th2 cDNA Libraryual Th2 cells, since this in vitro differentiation system
(A) Th2-specific expression in Th clones. Total RNA was isolateddoes not result in a complete shift to one subset. To-
from the panel of Th1 and Th2 clones either unstimulated or stimu-
gether, these experiments revealed that the cDNA iso- lated with anti-CD3 antibody and from M12 B lymphoma cells and
lated is selectively expressed in Th2 clones, where it is analyzed by Northern blot as described in Experimental Procedures.
induced upon T cell activation, and that it is absent from A control probe specific for GAPDH was used to show equal loading
of RNA.Th1 clones. Furthermore, this gene is induced in normal
(B) Up-regulation of Th2 cDNA during in vitro differentiation of nor-Thp when they are driven towards the Th2 lineage but
mal naive spleen cells into Th2 cells. In vitro T cell differentiationis not induced during Th1 development.
was performed as described in Experimental Procedures. Total RNAThe cDNA obtained from the yeast two-hybrid screen
was isolated from cells harvested at the indicated time-points. Cul-
was used as a probe to isolate a full-length cDNA from ture supernatant at the appropriate dilution was measured for cyto-
the D10 Th2 cell cDNA library. Sequence analysis re- kine (IL-10) production by ELISA to determine differentiation into the
vealed that this Th2-specific gene was identical to the Th1 or Th2 lineage. The data are representative of two independent
experiments.c-maf proto-oncogene, although the 4.3 kb clone we
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Figure 3. Transactivation of the IL-4 Promo-
ter by c-Maf
AE7 (A) or M12 (B) cells were transiently
transfected with a wild-type IL-4 CAT re-
porter, containing the region (2157 to 168)
of the murine IL-4 promoter, and indicated
expression vectors. Half of each sample was
stimulated 24 hr after transfection with anti-
bodies to CD3. All samples were harvested
48 hr after transfection, and relative CAT ac-
tivities were determined. (A) is the average of
two independent experiments; (B) is one of
three independent experiments. See the leg-
end to Table 1 for a description of the expres-
sion plasmids used.
obtained had an additional 1.6 kb of 39 untranslated cells. Stimulation of M12 cells with a PMA/Ca21 iono-
phore, which should result in translocation of NF-ATs tosequence when compared with previously published
isolates (Kerppola and Curran, 1994). the nucleus and induction of other AP-1 family members
(Flanagan et al., 1991; Jain et al., 1993), increased the
basal activity of the IL-4 promoter, but a marked induc-Ectopic Expression of c-Maf in Th1 and B
tion in promoter activity by c-Maf was still present (aver-Cells Transactivates the IL-4 Promoter
age z25-fold). c-Maf did not transactivate a controlThe identification of this cDNA as a member of the AP-
reporter driven by NF-AT multimers, demonstrating1/CREB/ATF gene family, together with its selective ex-
specificity of transactivation (data not shown). One rep-pression in Th2 cells, raised the possibility that c-Maf
resentative experiment and a summary of three indepen-controlled the tissue-specific transcription of the IL-4
dent experiments are shown in Figure 3B and Table 1.gene. The presence of transcripts encodingc-Maf corre-
lated well with IL-4 expression in Th2 cells and in 3
Table 1. c-Maf Transactivates the IL-4 Promoter Synergisticallyof 4 transformed mast cell lines examined (data not
with NF-ATpshown).
CAT ActivityTh1 clones and the B lymphoma M12 do not express
(Fold Induction)bc-Maf (Figure 2A) nor do they transcribe the IL-4 gene. PMA
If c-Maf is a transcription factor critical for controlling Expression Constructs Ionomycin Exp. 1 Exp. 2 Exp. 3
IL-4 gene expression, then ectopic expression in these
Control 2 1 1 1
cells should permit IL-4 gene expression. To test this,
1 7.6 1 1.4
the full-length c-Maf cDNA was cotransfected with an c-Maf 2 95 5 18.6
IL-4 promoter (2157 to 168) reporter plasmid into the 1 186 7 37
c-Fos 2 2.7 1 0.8Th1 clone AE7. We have previously shown that Th2-
1 7.6 1.2 1specific inducible IL-4 expression can be directed by
JunD 2 ND 0.9 0.5as little as 157 bp of the proximal IL-4 promoter. In
1 ND 1.4 1.9
Figure 3A, we show that ectopic expression of c-Maf NF-ATp 2 14.2 1.6 0.3
resulted in substantial activity of the IL-4 promoter in 1 41.2 3.5 0.3
the Th1 clone AE7 after stimulation through the TCR. c-Maf 1 NF-ATp 2 136 54 26.3
1 138 100 54.7The fold induction observed was approximately 5-fold
c-Fos 1 NF-ATp 2 7.4 1.6 3over that observed with the control vector alone.
1 15.4 1.9 6.1To test more rigorously the ability of c-Maf to trans-
Summary of three independent transient transfection experimentsactivate the IL-4 promoter in another non-IL-4-produc-
in M12 cells showing transactivation of the IL-4 promoter by c-Mafing cell, we performed the same experiment in the B
and synergy between c-Maf and NFATp. In Experiment 1, 20 mg oflymphoma cell line, M12. Normal B cells and B lym-
cell lysate was incubated for 2 hr. In Experiments 2 and 3, only 5
phoma cells do not produce IL-4. The results, shown in
mg of cell lysate was incubated for 1 hr in order to reveal synergy
Figure 3B and Table 1, confirmed our findings in the between c-Maf and NFATp.
Th1 clone. Ectopic expression of c-Maf resulted in a aControl is pMEX-NeoI.pREP4, c-Maf is pMEX-Maf/pREP4, c-Fos is
pMEX-c-Fos/pREP4, JunD is pMEX-JunD/pREP4, NF-ATp is pMEX-dramatic increase in the activity of the IL-4 promoter in
NeoI/pREP4-NF-ATp.unstimulated M12 cells. The fold induction observed,
bFold induction relative to control, unstimulated.when compared with transfection of a control vector,
ND, not done.
averaged approximately 50-fold in unstimulated M12
c-Maf Directs Th2-Specific IL-4 Expression
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As a control for the specificity of c-Maf as opposed
to the classic AP-1 family members, the c-Fos and c-Jun
proteins were also overexpressed in M12 cells, utilizing
the same mammalian expression vector together with
the IL-4 reporter plasmid. No IL-4 promoter activity
could be achieved through overexpression of these two
AP-1 family members. Thus, c-Maf hasa uniqueability to
drive IL-4 gene transcription in M12B cells. Furthermore,
overexpressionof c-Maf in the hepatoma cell line HepG2
also resulted in IL-4 promoter transactivation of approxi-
mately 100-fold (data not shown). We conclude from
these experiments that the provision of c-Maf to c-Maf-
negative Th1 or B cells, or to nonlymphoid cells, permits
transactivation of the IL-4 promoter.
Figure 4. Endogenous IL-4 Production in M12 Cells by Ectopic Ex-NF-AT proteins have been shown to be critically im-
pression of c-Maf and NF-ATpportant in the regulation of both the IL-4 and IL-2 cyto-
M12 cells were transfected with the indicated expression vectorskines. NF-ATp was the first member of this family to be
and cultured in selective media containing G418 (neomycin) andisolated (McCaffrey et al., 1993). Both AE7 and M12 cells
hygromycin. Single or double drug-resistant cells were washed and
have endogeneous NF-ATp protein butdo not transcribe resuspended at 5 3 105 cells/ml, and 200 ml of supernatant from
IL-4. Although NF-ATp could not, therefore, account for each sample was subjected to ELISA for cytokine quantitation.
selective IL-4 gene transcription, we wished to test
whether overexpression of NF-ATp in unstimulated or
stimulated M12 cells would further increase the trans- A Site in the IL-4 Promoter Is Footprinted
activation of the IL-4 promoter by c-Maf. Overexpres- by Extracts from Th2 but Not Th1 Clones
sion of NF-ATp alone resulted in some modest trans- The experiments shown above demonstrated a clear
activation of the IL-4 promoter in M12 cells. This functional role for c-Maf in controlling the tissue-specific
transactivation was markedly increased by ectopic ex- expression of IL-4. Furthermore, c-Maf transcripts were
pression of c-Maf, an increase that was not additive expressed in Th2 but not Th1 cells. However, we were
but synergistic (Figure 3B; Table 1). In contrast, c-Fos unable to detect differences in DNA–protein complexes
overexpression did not further increase the modest formed on the IL-4 promoter when using nuclear ex-
transactivation achieved by NF-ATp. We conclude that tracts prepared from Th2 as compared with Th1 cells
c-Mafand NF-ATp interact to achieve maximal induction by electrophoretic mobilityshift assays (EMSA) (data not
of the IL-4 promoter, the tissue specificity being pro- shown). To examine further whether there were proteins,
vided by c-Maf. such as c-Maf, in Th2, as opposed to Th1, nuclear ex-
tracts that might selectively bind IL-4 promoter se-
Ectopic Expression of c-Maf Activates
quences, the more sensitive technique of DNAase I foot-
Transcription of the Endogeneous IL-4
printing was used. We activated two Th2 clones (D10,Gene in a B Lymphoma
CDC35) and two Th1 clones (AE7, S53) by ligation of the
c-Maf clearly transactivates the IL-4 promoter in tran-
TCR with plate-bound anti-CD3 antibody, and nuclear
sient transfection assays in Th1, B, and nonlymphoid
extracts were prepared at time 0 (unstimulated), 2 hr,cells. To test whether expression of c-Maf in non-IL-4-
and 6 hr later. DNAase I footprinting analysis was thenproducing cells can activate the transcription of endo-
performed using an IL-4 promoter fragment (2157 togeneous IL-4, the B lymphoma M12 was stably trans-
168). Stimulated extracts from both Th1 and Th2 cellsfected with c-Maf, NF-ATp, or both. Stably transfected
footprinted the two NF-AT sites and the AP-1 site up-unstimulated M12 cells were plated at the same den-
stream of the distal NF-AT site, as described previouslysity and supernatants harvested 24 hr later to measure
(Rooney et al., 1995b), consistent with the demonstratedcytokines by ELISA. Figure 4 shows that M12 cells
function of NF-AT and AP-1 proteins in regulating bothtransfected with c-Maf or NF-ATp alone did not produce
the IL-2 and IL-4 promoters (Rooney et al., 1995a,measurable IL-4 by ELISA. However, M12 cells stably
1995b). Furthermore, inspection of the autoradiographtransfected with both c-Maf and NF-ATp did produce
revealed an area of hypersensitivity on the noncodingdetectable, but low level, IL-4 by ELISA. This was con-
strand at residues 228 and 229 when extracts fromfirmed by RT–PCR of RNA from these cells (data not
stimulated Th2 but not stimulated Th1 cells were usedshown). In contrast, M12 cells transfected with c-Maf
(Figure 5A). Unstimulated Th cell extracts did not foot-and NF-ATp did not produce detectable IL-2 (data not
print this region (Figure 5A). The Th2 footprint observedshown). The requirement for both c-Maf and NF-ATp is
was subtle, but reproducible in two experiments, and isconsistent with the synergistic effect of these factors in
located in a site we had previously demonstrated to bethe transactivation of the IL-4 promoter noted in the
critical for IL-4 promoter activation in Th2 cells (Hodgetransient transfection experiments in M12 cells. In con-
et al., 1995). A schematic summary of sites occupied intrast, stable transfection of M12 cells with junD, an AP-1
the IL-4 promoter as detected by footprint analysis isfamily member that can increase IL-4 expression in Th2
shown in Figure 5B. We conclude that a site in the proxi-cells (Rooney et al., 1995b), alone or together with NF-
mal IL-4 promoter, previously shown to be functionallyATp did not result in IL-4 production. These results dem-
important, is occupied in activated Th2 but not in acti-onstrate the essential and selective role of c-Maf in di-
recting tissue-specific endogeneous IL-4 production. vated Th1 cells.
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Figure 5. A Th2-Specific Footprint Is Imme-
diately Downstream of the Putative MARE
Site in the IL-4 Promoter
(A) DNAase I footprint was performed using
nuclear extracts from Th1 (D10, CDC35) or
Th2 (AE7, S53) clones harvested at the indi-
cated time-points after stimulation with anti-
CD3. Two Th2-specific hypersensitive resi-
dues on the noncoding strand of the IL-4
promoter are indicated by an asterisk. We ran
5 lanes of a DNAase I digestion of the IL-4
promoter probe (without nuclear extract) and
a Maxam–Gilbert A/G ladder were run next to
DNAase I-treated samples.
(B) Schematic representation of the proximal
regulatory region of the murine IL-4 promoter
and the 4 bp mutants used in Figure 6. The
top portion shows the primary sequence of
the murine IL-4 promoter. The numbers indi-
cated are relative to the start site of transcrip-
tion at 11. Asterisks denote the Th2-specific
hypersensitive residues seen on DNAase I
footprint. The bottom portion shows the se-
quences of the wild-type (259 to 228) oligo-
nucleotide and the 4 bp mutants used in
EMSA and the functional assays in Fig-
ure 6. Altered nucleotides are shown in low-
ercase bold and correspond to the numbering
system shown above.
Recombinant c-Maf Binds to a MARE Site presence of DNA, recombinant NF-ATp and c-Maf pro-
teins were used separately or together in EMSA within the IL-4 Promoter
The Th2-specific footprint does not contain a MARE. the 33 bp oligonucleotide containing both the NF-AT
However, examination of the proximal IL-4 promoter and adjacent MARE sites. Each protein alone bound to
revealed a half c-Maf binding site (MARE) (residues 242 IL-4 promoter DNA. Recombinant c-Maf plus recombi-
to 237) immediately downstream of the proximal NF-AT nant NF-ATp protein produced these complexes and,
site (residues 256 to 251) (Figure 5B) and immediately in addition, formed a higher mobility complex (Figure 6).
upstream of the Th2 footprint. We had previously dem- No higher mobility complex was observed when c-Jun
onstrated that mutation of this site abolished activity of and NF-ATp proteins were used, consistent with the
the IL-4 promoter in Th2 cells (Hodge et al., 1995). To failure of c-Jun to bind this site. We conclude that c-Maf
determine whether c-Maf bound this site, a truncated
c-Maf recombinant protein containing the b-zip domain
(amino acids 171–370) was expressed in E. coli, purified
on an S-Tag agarose column, and used in EMSA with
radiolabeled T-MARE oligonucleotide. The recombinant
protein bound well to both a consensus T-MARE oligo-
nucleotide and to a 33 bp oligonucleotide containing
the NF-AT site and MARE present in the IL-4 promoter.
Furthermore, c-Maf did not bind to an oligonucleotide
containing only the NF-AT target sequence to which
recombinant NF-ATp bound well. The ability of c-Maf
to bind to the IL-4 promoter probe was specific, since
in vitro translated c-Jun protein did not bind to this
oligonucleotide (Figure 6), nor did recombinant c-Jun
protein footprint the MARE site in previously published
experiments (Rooney et al., 1995b). The c-Jun protein
was functional since it could bind to the consensus
MARE oligonucleotide, which contains a core TRE site.
We conclude that c-Maf, but not another AP-1 family
member (c-Jun), can bind the T-MARE sequence within
the proximal IL-4 promoter.
NF-ATproteins interact cooperatively with AP-1 family
member proteins to form higher mobility complexes on Figure 6. c-Maf, but Not c-Jun, Binds to the Proximal IL-4 Promoter
IL-2 and IL-4 promoter DNA on EMSA (Jain et al., 1993; and Forms a Complex with NF-ATp
Rooney et al., 1995b). That they might do so with c-Maf EMSA was performed using the indicated proteins and labeled ds-
was suggested by the functional studies above. To de- oligonucleotides as described inExperimental Procedures. The non-
specific band is seen with the reticulocyte lysate control.termine whether c-Maf interacted with NF-AT in the
c-Maf Directs Th2-Specific IL-4 Expression
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can specifically bind in vitro to a sequence located in
theproximal IL-4 promoter, previouslyshown tobe func-
tionally critical in Th2 cells, and that, like other AP-1
proteins, it can interact in vitro with NF-AT proteins.
The Ability of c-Maf to Transactivate the IL-4
Promoter Maps to the MARE
and Th2-Specific Footprint
We have previously characterized an essential region
of the IL-4 promoter located immediately upstream of
the TATA element. High resolution mutagenesis of this
33 bp region (259 to 227) demonstrated multiple sites
required for inducible IL-4 transcription (Hodge et al.,
1995). These sites included an NF-AT target sequence,
the region footprinted by Th2 extracts, and what we now
recognize as a MARE. A series of 4 bp linker-scanning
mutants generated across this region were used to map
the target sequence utilized by c-Maf in vivo. M12 cells
were cotransfected with c-Maf and this series of IL-4
promoter mutants. Mutation of the MARE (mutants 3
and 4), or the site defined by the Th2-specific footprint
(mutant 2), abrogated (mutants 2 and 4) or partially abro-
gated (mutant 3) the ability of transfected c-Maf to drive
IL-4 transcription (Figure 7A). A modest effect in reduc-
ing c-Maf transactivation was also observed for mutant
8, which disrupts the NF-AT sequence, consistent with
the presence in M12 cells of endogeneous NF-ATp and
with the synergy between NF-ATp and c-Maf shown
above. Mutants 6 and 7 had no significant effect, while
mutant 5 had enhanced transactivation ability, consis-
tent with previous observations (Hodge et al., 1995). The
transactivation data is consistent with EMSA performed
Figure 7. Transactivation of the IL-4 Promoter by c-Maf Maps towith recombinant c-Maf protein, using as probe an oligo-
the MARE and Th2-Specific Footprint
nucleotide that contains this 33 bp region and these
(A) M12 cells were cotransfected with a c-Maf expression vectormutant oligonucleotides as cold competitors (Figure
and either the wild-type IL-4 CAT reporter or the 4 bp mutants shown
7B). We conclude from these experiments that c-Maf in Figure 5B. We incubated 10 mg of each cell lysate at 378C for 2
specifically binds to and transactivates the MARE and hr, and relative CAT activities were determined. The average of three
independent experiments and one representative experiment arethat the adjacent Th2-specific element is intimately in-
shown in the top and bottom portions, respectively.volved in both the binding and function of c-Maf.
(B) EMSA was performed using recombinant c-Maf and the IL-4
promoter (259 to 227) probe. Indicated unlabeled ds-oligonucleo-
tides, in 50- and 100-fold molar excess, were used as cold compet-Discussion
itors.
CD4 Th cells have been subdivided into two subsets on
the basis of their pattern of cytokine secretion. However,
the molecular basis for this selective expression of cyto- downstream of the MARE that is occupied by proteins
in Th2 but not Th1 extracts. This region of the proximalkines has remained elusive and cannot be attributed to
already identified transcription factors such as NF-AT IL-4 promoter is intimately involved in both the binding
and function of c-Maf.and AP-1 family members known to regulate multiple
cytokine genes. Here, we provide strong evidence that We found no evidence for transcriptional silencing
as the mechanism of Th-selective cytokine expression,the selective expression of the c-maf proto-oncogene
in Th2 cells accounts for tissue-specific IL-4 expression since somatic cell fusion of a Th1 and a Th2 clone re-
sulted in the production, rather than the extinction, ofin these cells. c-Maf is expressed only in Th2 and not
in Th1 cells and is induced, together with IL-4, in the both the IL-2 and IL-4 cytokines. This is consistent with
earlier findings that fusion of a Th1 clone that producedformer upon transmission of signals through the TCR.
Furthermore, c-Maf is induced during the development only IL-2 with a cytotoxic T cell clone that produced
only IFNg resulted in the production of both cytokinesof normal Thp cells along a Th2 but not a Th1 lineage,
and forced expression of c-Maf transactivates an IL-4 rather than neither cytokine (Havran and Fitch, 1987).
Since the IL-2 silencer described earlier (Mouzaki etpromoter in Th1, B, and nonlymphoid cells. Moreover,
when both c-Maf and NF-ATp are introduced, B cells al., 1991) could be overcome by proteins present in
activated T cell extracts, it is possible that silencers arecan produce endogeneous IL-4. The binding of c-Maf
and its transactivation of the IL-4 promoter both map operative in early Thp but not differentiating T cells. Our
results made it more likely that cytokine specificity inin the proximal IL-4 promoter to a MARE and a site just
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mature Th cells was achieved through the action of tis- have demonstrated that the interferon-b chain is down-
sue-specific activators. regulated in Th2 cells during differentiation, but this ap-
A thorough analysis of the IL-4 promoter in search pears to be a ligand-induced event rather than a conse-
of such activators has revealed functionally important quence of tissue-specific Th cell differentiation. There
binding sites for several transcription factors, including has also been a report that the Fas ligand receptor is
NF-AT, CCAAT box binding protein NF-Y, Oct 1, HMG preferentially, although not solely, expressed on Th1
I(Y), AP-1 members, NF-kB, and an as yet unpurified clones rather than Th2 clones (Suda et al., 1995), but
factor termed PCC (Abe et al., 1992; Todd et al., 1993; FasL expression has not been examined during normal
Szabo et al., 1993; Lederer et al., 1994; Rooney et al., T cell differentiation. c-maf is therefore the only Th2-
1995b;Hodge et al., 1995; Chuvpilo et al., 1993). Silencer specific noncytokine gene to be identified to date. Analy-
elements further upstream that bind factors termed NRE sis of the c-Maf promoter should provide insights into
have also been described (Le-Weber et al., 1993). None other factors that direct Th2-specific gene expression.
of these factors is expressed in a Th-selective manner. Within the lymphoid lineage, c-Maf is clearly restricted
Selective usage of NF-AT proteins by Th1 versus Th2 to Th2 cells. The failure of Th1 cells or B cells to tran-
cells is unlikely, since NF-ATc is present in nuclear ex- scribe IL-4 is easily explained by the absence of c-Maf.
tracts of both subsets (M. R. H., unpublished data) and However, outside the lymphoid system, c-Maf is fairly
NF-ATp-deficient mice continue to produce both IL-2 widely expressed in organs such as kidney, testis, pla-
and IL-4 (Hodge et al., 1996). Finally, although there has centa, and skeletal muscle. If c-Maf singlehandedly di-
beensome evidence that differential regulation of NF-kB rects IL-4 transcription, why is no IL-4 produced in such
may contribute to differences in cytokine transcription nonhematopoietic tissues? One explanation is that there
between Th subsets (Lederer et al., 1996), the ubiquitous are multiple isoforms of c-Maf, one of which is Th2-
expression of p65 and p50 makes them unlikely candi- selective. Indeed, several members of the maf family
dates for directing Th-specific control. Recently, it has have already been identified, some of which (MafK,
been shown that CCAAT enhancer–binding protein (C/ MafF, p18) may be repressors of c-Maf. Although we
EBPb) (NF–IL-6), originally isolated by virtue of its ability have preliminary evidence for an additional c-Maf family
to regulate IL-6, a cytokine preferentially made by Th2 member that is ubiquitously expressed (I.-C. H., unpub-
rather than Th1 cells, can bind to a site that overlaps lished data), the cDNA we isolated from Th2 cells does
the MARE. Furthermore, overexpression of C/EBPb in- not obviously differ from published isolates aside from
creased IL-4 promoter transactivation in IL-4-producing additional 39 untranslated sequence. An attractive pos-
Jurkat cells (Davydov et al., 1995). It is not known sibility is that other forms of maf, such as mafK, may
whether C/EBPb could permit IL-4 gene transcription silence the IL-4 promoter in nonlymphoid cells but are
in Th1 cells. This is unlikely, however, as C/EBPb is displaced in Th2 cells by c-Maf, as has been suggested
expressed in both Th1 and Th2 cells (I.-C. H., unpub- for p18 and the other small Mafs in regulating b-globin
lished data). One interesting possibility is that c-Maf and gene expression in the erythroid lineage (Igarashi et al.,
C/EBPb, both b-zip proteins, may interact to transacti- 1994; Kataoka et al., 1995). A gradient of expression of
vate the IL-4 promoter, the tissue specificity being pro- the various transcriptional activator and repressor maf
vided by c-Maf. proteins might exist that ultimately determines whether
The Th2-specific expression of c-Maf describedin this a given cell will produce IL-4. The ability of c-Maf overex-
report made it an obvious candidate for a transcription pression to transactivate the IL-4 promoter in HepG2
factor responsible for dictating Th2-selective IL-4 gene liver cells is consistent with this explanation. A careful
transcription. It should be noted that the site identified analysis of the relative levels of expression and tran-
in our studies differs from the consensus MAREs pre-
scriptional activities of all maf family members in
viously described. Although it has a consensus core
lymphoid and nonlymphoid tissues will be necessary
TRE, the IL-4 T-MARE is not palindromic and its flanking
to test this hypothesis. It is also possible that other
sequences are dissimilar from other MAREs. However,
lymphoid-specific factors, such as NF-ATc, are requiredthe consensus MARE was identified through binding-
for transcriptional activation of Th-specific cytokines.site selection with recombinant c-Maf protein, an ap-
Their absence in nonhematopoietic tissues prevents aproach that may not reflect the interactions of c-Maf
Th-selective factor, such as c-Maf, from driving IL-4with other factors in vivo (Kataoka et al., 1994). The
gene transcription in these sites. Such factors may bebinding and transactivation data presented in this report
necessary for cytokine transcription but do not directprovide strong evidence that the IL-4 promoter site is a
Th subset–selective transcription. The requirement forbonafide MARE. Interestingly, a region of the IL-4 pro-
both NF-ATp and c-Maf to achieve endogeneous IL-4moter encompassing the MARE and Th2 footprint was
production in the B lymphoma provides some evidenceshown to be preferentially expressed in Th2 as com-
in favor of this possibility. Of course, these explanationspared with Th1 cells by Lenardo and colleagues (Bruhn
are not mutually exclusive.et al., 1993).
Identification of a Th2-specific transcription factorOne approach to altering Th1/Th2 ratios is to identify
that controls the production of IL-4 and, hence, the con-genes that are specifically and selectively expressed in
tinued formation of Th2 cells may allow the selectiveTh1 or Th2 cells. Manipulation of such gene products
manipulation of Th subsets in vivo. Blockade of c-Mafmight allow the conversion of these subsets or might
may inhibit Th2 formation and pathogenic immunoglob-enhance the formation of one subset. To date, no Th1 or
ulin E antibodies in allergic diseases while enhancingTh2 genes other than the cytokines have been identified.
Two recent reports (Bach et al., 1995; Pernis et al., 1995) the immune response to malignant cells and infectious
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media and stimulated with plate-bound anti-CD3 antibody (Phar-agents. In contrast, up-regulation of c-Maf in autoimmu-
mingen, San Diego, CA), 1 mg/ml in 13 PBS overnight at 48C ornity and in the setting of organ transplantation may per-
with 50 ng/ml PMA (Sigma, St. Louis, MO) and 1 mM ionomycinmit enhanced Th2 formation at the expense of Th1 cell
(Calbiochem Corporation, La Jolla, CA) for 24 hr. Cell lysate was
development with subsequent dampening of the im- prepared by freeze–thaw lysis in 0.25 M Tris–HCl (pH 7.8). Equal
mune response. The predominance of Th2 cells ob- amounts of protein (between 5–20 mg) were used for CAT assays.
CAT assays were performed as previously described (Todd et al.,served in the setting of neonatal tolerance suggests that
1993).this may be an attractive approach (Forsthuber et al.,
For stable transfection, M12 cells were transfected as described1996). Forced expression of c-Maf in all T cells in
above. The transfected cells were allowed to recover in completetransgenic mice, combined with targeted disruption of
media for 48 hr before the addition of neomycin (GIBCO/BRL, Gaith-
the c-maf gene, should allow us to evaluate such possi- ersburg, MD) and hygromycin (Calbiochem Corporation) at a con-
bilities in vivo. centration of 400 mg/ml of each antibiotic. The transfected cells
were supplemented with fresh media every other day.
Experimental Procedures
In Vitro T Cell Differentiation
Splenic cell suspensions were prepared from 6- to 8-week-oldCell Culture
BALB/c mice, cultured in RPMI 1640 supplemented with 10% FCSMurine Th1 (D1.1, OF6, Ar5, AE7, and S53) and Th2 (D10. G4 and
at a density of 106 cells/ml, and stimulated with plate-bound anti-CDC35) clones used in this study have been previously described
CD3 antibody in the presence of 5 mg/ml anti-IL-4 antibody (11B11)(Lederer et al., 1994; Barve et al., 1994). A non-IL-4-producing sub-
for the Th1 lineage, or 5 mg/ml anti-IFNg antibody (XMG-1) for theclone of AE7 (gift of M. Lenardo), as determined by RT–PCR for
Th2 lineage (Hsieh et al., 1995). We added 50 U/ml IL-2 to all cultures,cytokines, was used. All clones were cultured in RPMI 1640 supple-
and 500 U/ml IL4 (Genzyme) to Th2 cultures 24 hr after stimulation.mented with 10% FCS and 10% ConA-stimulated rat splenocyte
All cells were harvested, washed, and restimulated 7 days after thesupernatant, and maintained by biweekly stimulation with ap-
primary stimulation with plate-bound anti-CD3 antibody.propriate antigen and APCs. M12.4. C3 (M12) is a murine B lym-
phoma cell line and was cultured in RPMI 1640 supplemented with
ELISA for Cytokine Quantitation10% FCS.
All anti-cytokine antibodies were purchased from Pharmingen.
ELISA was performed according to the instructions of Pharmingen
Th Cell Fusion and Cytokine Analysis and as described (Hodge et al., 1996), with the exception that avidin–
The Th1 clone D1.1 (Kd) and the Th2 clone D10 (Kk) were fused alkaline phosphatase (Sigma) at 1:500 dilution in PBS/BSA was used
according to the suspension cell fusion procedure (Laneet al., 1986). in place of avidin–peroxidase. P-nitrophenyl phosphate (GIBCO/
After fusion, the cells were allowed to recover for 8 hr and then BRL) at 4 mg/ml in substrate buffer (10% diethanolamine, 0.5 mM
double-stained using PE-conjugated anti-Kk and FITC-conjugated MgCl2, 0.02% sodium azide [pH 9.8]) was used as substrate.anti-Kd antibodies (Pharmingen, La Jolla, CA). Cells were then sorted
on the basis of size to distinguish unfused cells from heterokaryons
RNA Isolation and Northern Analysis
and homokaryons and by fluorescence to identify single-positive
Total RNA was prepared by using Trizol (GIBCO/BRL) according to
and double-positive cells. As indicated in Figure 1A, three popula-
the instructions of the manufacturer. Total RNA (10 mg) from each
tions were sorted for the following: large PE-positive cells (D1.1 3
sample was fractionated on a formaldehyde agarose gel and trans-
D1.1), large FITC-positive cells (D10 3 D10), and large PE-positive
ferred to a nylon membrane. A 300 bp DraI fragment derived from
and FITC-positive cells (D1.1 3 D10). Approximately 5 3 105 cells
the 39 untranslated region of c-maf was labeled with [a-32P]dCTP
were obtained for each population. Routinely, 5%–10% of the cells
using a Random Primed DNA Labeling Kit (Boehringer Mannheim,
had undergone fusion. Each of these three populations was then
Indianapolis, IN). Hybridization was performed using QuikHyb (Stra-split in half, with one half transferred to prerinsed anti-CD3-coated
tagene) according to the instructions of the manufacturer.plates and the remaining half to uncoated plates. After 4 hr, the
cells were harvested and poly(A)1 RNA–isolated using the Micro-
Recombinant Proteins and In Vitro Transcription/TranslationFastTrack kit (Stratagene, La Jolla, CA). cDNA was made using the
The recombinant NF-ATp, containing the Rel domain of human NF-SuperScript kit (GIBCO/BRL, Bethesda, MD), and used for PCR
ATp, was a gift of T. Hoey. The expression vector for recombinantanalysis with commercially available primers specific for murine IL-2,
c-Maf was constructed by inserting a cDNA fragment encodingIL-4, and b-actin, according to the instructions of the manufacturer
amino acid residues 171–370 of c-Maf into the NotI site of pET29(Stratagene). PCR reactions included 0.5 mCi [a-32P]dCTP (3000 Ci/
(Novagene, Incorporated, Madison, WI). The truncated c-Maf protein
mmol) (NEN Dupont, Boston, MA). PCR products were separated by
was expressed using T7 polymerase in the BL21(DE3) strain. Cellsnondenaturing PAGE and dried and visualized by autoradiography.
were induced by the addition of 1 mM IPTG and incubated at 378C
for 3 hr. The induced cells were lysed in 13 Bind/Wash buffer (20
Reporters and Expression Vectors mM Tris–HCL [pH 7.5], 150 mM NaCl, 0.1% Triton X-100) followed
The generation of the wild-type IL-4 CAT reporter, containing an by sonication. The c-Maf protein was then purified from the soluble
IL-4 promoter fragment from 2157 to 168, and its 4 bp mutants fraction by using the S-Tag Purification Kit (Novagen) according
was previously described (Hodge et al., 1995). Expression vectors to the instructions of the manufacturer. The in vitro transcription/
containing the murine full-length cDNAs encoding c-Fos and JunD translation vector TP7-NF-ATp, a gift of T. Hoey, contains a cDNA
in the vector of pMEX–NeoI were a gift of R. Bravo. The expression fragment encoding the Rel domain of human NF-ATp; pGEM-c-Jun
vector for c-Maf was constructed by inserting a full-length cDNA was constructed by inserting a full-length murine c-jun cDNA into
into the SalI site of pMEX–NeoI. The expression vector pREP4–NF- the PstI site of pGEM4. Each plasmid DNA (1 mg) was transcribed
ATp, containing the full-length murine NF-ATp cDNA, was the gift from the T7 promoter and translated in rabbit reticulocyte lysate
of T. Hoey. by using the TnT Coupled Transcription/Translation Kit (Promega,
Madison, WI).
Transfection and CAT Assays
AE7 or M12 cells were transiently transfected by preincubating 0.4 EMSA
We end-labeled 100 ng of double-stranded oligonucleotides withml of cells, containing 2 3 107/ml AE7 or 3 3 106/ml M12 cells in
serum-free RPMI 1640 with 20 mg (AE7) or 5 mg (M12) of each 32P-dATP (DuPont NEN Research Product, Wilmington, DE) using
T4 polynucleotide kinase (Pharmacia LKB Biotechnology, Incorpo-plasmid for 10 min at room temperature. The samples were then
electroporated using a Bio-Rad Gene Pulser (Bio-Rad, Richmond, rated, Piscataway, NJ). The labeled ds-oligonucleotides were frac-
tionated on 15%–20% polyacrylamide gels, eluted overnight at 378CCA) set at 975 mF, 280 V, and immediately placed on ice for 10 min.
The transfected cells were allowed to recover overnight in complete in 13 TE and precipitated in ethanol. Binding assays were performed
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at room temperature for 20 min using 0.5 mg of recombinant proteins (1993). Molecular dissection of the mouse interleukin-4 promoter.
Proc. Natl. Acad. Sci. USA 90, 9707–9711.or 4 ml of in vitro translated products, 500 ng poly(dI–dC), and 20,000
cpm of probe in a 15 ml volume of 20 mM HEPES (pH 7.9), 100 mM Chuvpilo, S., Schomberg, C., Gerwig, R., Heinfling, A., Reeves, R.,
KCl, 5% glycerol, 1mM EDTA, 5mM DTT, 0.1% NP-40, and 0.5 mg/ Grummt, F., and Serfling, E. (1993). Multiple closely-linked NFAT/
ml BSA. The samples were then fractionated in 4% nondenaturing octamer and HMG I (Y) binding sites are part of the interleukin-4
polyacrylamide gel containing 0.53 TBE at room temperature. promoter. Nucl. Acids Res. 21, 5694–5704.
Oligonucleotides derived from the murine IL-4 promoter are 259
Davydov, I.V., Krammer, P.H., and Li-Weber, M. (1995). Nuclear fac-to 227: 59-CTCATTTTCCCTTGGTTTCAGCAACTTTAACTC-39; 279
tor-IL6 activates the human IL-4 promoter in T cells. J. Immunol.to 260: 59-ATAAAATTTTCCAATGTAAA-39; and 288 to 261: 59-TGG
155, 5273–5279.TGTAATAAAATTTTCCAATGTAAA-39. The sequence of the MARE
Emmel, E.A., Verweij, C.L., Durand, D.B., Higgins, K.M., Lacy, E., andoligonucleotide is 59-GGAATTGCTGACTCAGCATTACT-39. All oligo-
Crabtree, G.R. (1989). Cyclosporin A specifically inhibits function ofnucleotides were annealed with their respective reverse–comple-
nuclear proteins involved in T cell activation. Science 246, 1617–mentary strands to form double-stranded oligonucleotides.
1620.
Flanagan, W.M., Corthesy, B., Bram, R.J., and Crabtree, G.R. (1991).DNAase I Footprinting
Nuclear association of a T-cell transcription factor blocked by FK-The preparation of nuclear extracts has been previously described
506 and cyclosporin A. Nature 352, 803–807.(Rooney et al., 1995b). DNA templates were made by digestion of
the IL-4 promoter fragment 2157 to 168 with XbaI, kinasing with Forsthuber, T., Yip, H.C., and Lehmann, P.V. (1996). Induction of TH1
[a-32P]dCTP and Klenow, digestion with SalI, and gel-purification and TH2 immunity in neonatal mice. Science 271, 1728–1730.
by PAGE followed by overnight elution and ethanol precipitation. Fujiwara, K.T., Kataoka, K., and Nishizawa, M. (1993). Two new
Approximately 100,000 cpm of probe (2–5 ng) was incubated with members of the maf oncogene family, mafK and mafF, encode nu-
equal amounts of nuclear extract prepared from different T cell clear b-zip proteins lacking putative trans-activator domain. Onco-
clones in a total volume of 50 ml of 25 mM HEPES (pH 7.9), 100 gene 8, 2371–2380.
mM KCl, 12.5 mM MgCl2, 0.05 mM EDTA, 1.0 mM DTT, 10% glycerol,
Goransson, M., Sonden, B., Nilsson, P., Dagberg, B., Forsman, K.,2% polyvinyl alcohol, and 0.5 mg of poly(dI-dC). We then added 50
Emanuelsson, K., and Uhlin, B.E. (1990). Transcriptional silencingml of 10 mM MgCl2, 5 mM CaCl2 in the presence of varying dilutions
and thermoregulation of gene expression in Escherichia coli. Natureof DNAase I. After 2 min of DNAase I digestion, the reactions were
344, 682–685.stopped by the addition of 100 ml of Stop mix consisting of 200
Havran, W.L., and Fitch, F.W. (1987). Characterization of murinemM NaCl, 20 mM EDTA, 1% SDS, and 50 mg/ml tRNA. Samples
cytolytic-helper hybrid T cell clones. Nature 325, 65–67.were then phenol-extracted, ethanol precipitated, and resuspended
in loading buffer (0.1% bromophenol blue, 0.1% Xylene cyanol, 90% Hodge, M.J., Rooney, J.W., and Glimcher, L.H. (1995). The proximal
formamide). An equivalent number of counts from each sample was promoter of the IL-4 gene is composed of multiple essential regula-
denatured at 908C for 3 min and loaded onto a 6% polyacrylamide– tory sites which bind at least two distinct factors. J. Immunol. 154,
42% urea gel, run at 80 W for 3 hr, dried, and exposed overnight. 6397–6405.
Maxam–Gilbert A/G ladders were run alongside the DNAase
Hodge, M.R., Ranger, A.M., Charles de la Brousse, F., Hoey, T.,
I-treated samples.
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